The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management
Open accessAbstract
Chronic obstructive pulmonary disease (COPD) is a common, complex and heterogeneous condition which is responsible for considerable and growing morbidity, mortality and healthcare expense worldwide. In order to decipher the complexity of COPD, it is imperative that we identify groups of patients with similar clinical characteristics, prognosis and/or therapeutic needs, so called clinical phenotypes. This strategy is logical for research but it may be of limited clinical value because clinical phenotypes may overlap in the same patient and the same clinical phenotype could result from different biological mechanisms. With the goal of matching assessment to treatment choices, the most recent iteration of GOLD reorganized treatment objectives into two categories (improving symptoms, i.e., dyspnoea and health status, and decreasing future risk, as predicted by FEV1 level and exacerbations history), thus moving closer to individualized medicine using currently available bronchodilators and anti-inflammatory medications. Yet, future therapeutic options are likely to include targeting endotypes which reflect subtypes of patients defined by a distinct pathophysiological mechanism. Specific biomarkers of these endotypes would be particularly useful for clinical practice, especially when clinical phenotype alone is insufficient to identify the underlying endotype. Currently, a limited series of potential COPD endotypes and biomarkers have been suggested. We will gain empiric knowledge from proof of concept trials in COPD with emerging drugs that target specific inflammatory pathways. In each instance, specific endotyping and biomarker efforts will likely be required for success of these trials, since the pathways are likely to be operative in only a subset of patients. Network analysis of human diseases offers the possibility of a better understanding of disease patho-biologic complexity while facilitating the development of new therapeutic alternatives and, importantly, a reclassification of complex diseases. All these development should pave the way towards personalized treatment of COPD in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Self-citationA New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Characterisation of COPD heterogeneity in the ECLIPSE cohort
the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators, Agusti, A., Calverley, P. M., Celli, B., Coxson, H. O., Edwards, L. D., Lomas, D. A., MacNee, W., Miller, B. E., Rennard, S., et al. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-122 · Cited by 1,157
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Mortality in COPD: role of comorbidities
Sin, D. D., Anthonisen, N. R., Soriano, J. B., & Agusti, A. G. (2006) · European Respiratory Journal · doi:10.1183/09031936.00133805 · Cited by 1,052
The exposome: a new paradigm to study the impact of environment on health
Vrijheid, M. (2014) · Thorax · doi:10.1136/thoraxjnl-2013-204949 · Cited by 351
Cited by
Singh, D., Agusti, A., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Criner, G. J., Frith, P., Halpin, D. M. G., Han, M., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00164-2019 · Cited by 1,937
Self-citationTreatable traits: toward precision medicine of chronic airway diseases
Agusti, A., Bel, E., Thomas, M., Vogelmeier, C., Brusselle, G., Holgate, S., Humbert, M., Jones, P., Gibson, P. G., Vestbo, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01359-2015 · Cited by 1,083
Self-citationChronic obstructive pulmonary disease
Rabe, K. F., & Watz, H. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31222-9 · Cited by 960
Agustí, A., Melén, E., DeMeo, D. L., Breyer-Kohansal, R., & Faner, R. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00555-5 · Cited by 315
Mayhew, D., Devos, N., Lambert, C., Brown, J. R., Clarke, S. C., Kim, V. L., Magid-Slav, M., Miller, B. E., Ostridge, K. K., Patel, R., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210408 · Cited by 285
Metadata
- Authors
- Woodruff, P. G., Agusti, A., Roche, N., Singh, D., & Martinez, F. J.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 385
- Issue
- 9979
- Pages
- 1789-1798
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2151267780
- Cited by
- 241
- References
- 7
- FWCI
- 30.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. https://app.cochat.ai/papers/10.1016/s0140-6736(15)60693-6
- The paper
- Woodruff, P. G., Agusti, A., Roche, N., Singh, D., & Martinez, F. J. (2015). Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. The Lancet. https://doi.org/10.1016/s0140-6736(15)60693-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.